TLR7 and basal cell carcinoma: In addition, TRAIL+ pDC infiltration is observed in basal cell carcinoma lesions treated with the topical TLR7 agonist IMQ, suggesting that TLR-activated pDCs contribute to rejection of cutaneous tumors [92,188].